# Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors

> **NCT00126620** · PHASE1 · COMPLETED · sponsor: **University Health Network, Toronto** · enrollment: 17 (actual)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **DRUG:** erlotinib hydrochloride
- **DRUG:** sorafenib tosylate

## Key facts

- **NCT ID:** NCT00126620
- **Lead sponsor:** University Health Network, Toronto
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2011-05
- **Final completion:** —
- **Target enrollment:** 17 (ACTUAL)
- **Last updated:** 2015-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00126620

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00126620, "Sorafenib and Erlotinib in Treating Patients With Metastatic or Unresectable Solid Tumors". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT00126620. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*